INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA

被引：0
|
作者：
Porter, J. [1 ]
Cappellini, M. D. [2 ]
Origa, R. [3 ]
Forni, G. L. [4 ]
Laadem, A. [5 ]
Galacteros, F. [6 ]
Voskaridou, E. [7 ]
Miteva, D. [5 ]
Sung, V. [5 ]
Chopra, R. [5 ]
Arlet, J. B. [8 ]
Ribeil, J. A. [8 ]
Klesczewski, K. [5 ]
Attie, K. [9 ]
Garbowski, M. [1 ]
Graziadei, G. [2 ]
Balocco, M. [4 ]
Hermine, O. [8 ]
机构：
[1] UCL, London, England
[2] Univ Milan, Ca Granda Fdn IRCCS, Milan, Italy
[3] Univ Cagliari, Osped Reg Microcitemie, Cagliari, Italy
[4] Ente Osped Osped Galliera, Genoa, Italy
[5] Celgene Corp, Summit, NJ USA
[6] Grp Hosp Henri Mondor, Creteil, France
[7] Laikon Gen Hosp, Athens, Greece
[8] Hop Necker Enfants Malad, Inst Imagine, Paris, France
[9] Acceleron Pharma, Cambridge, MA 02139 USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S662
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [21] SAFETY, TOLERABILITY, AND EFFICACY OF REPEAT-DOSE INJECTIONS OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A PROSPECTIVE, OPEN-LABEL, PHASE 3 STUDY
    Kerscher, Martina
    Connolly, Simon A.
    Biwer, Bernard
    Weissenberger, Petra
    Kestemont, Philippe
    Noah, Ernst M.
    Sattler, Gerhard
    Trevidic, Patrick
    TOXICON, 2018, 156 : S60 - S60
  • [22] Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study
    Fischer, Tanja
    Sattler, Gerhard
    Prager, Welf
    Rzany, Berthold
    Pavicic, Tatjana
    Gauglitz, Gerd
    Weissenberger, Petra
    Riaz, Shahbaz
    Kerscher, Martina
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (05) : 461 - 469
  • [23] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
    Howard Jr, James F.
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said R.
    Pasnoor, Mamatha
    Guglietta, Antonio
    Van Hoorick, Benjamin
    Steeland, Sophie
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [24] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY
    Vannucchi, A. M.
    DeAngelo, D. J.
    Reiter, A.
    Radia, D.
    Deininger, M. W.
    George, T. I.
    Panse, J.
    Jentzsch, M.
    Alvarez-Twose, I.
    Mital, A.
    Hermine, O.
    Dybedal, I.
    Hexner, E. O.
    Hicks, L. K.
    Span, L.
    Mesa, R.
    Bose, P.
    Pettit, K. M.
    Heaney, M. L.
    Oh, S.
    Sen, J.
    Lin, H-M.
    Mar, B. G.
    Gotlib, J.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 2
  • [25] Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata: interim results from the ALLEGRO-LT phase 3, open-label study
    Tsianakas, Athanasios
    Sinclair, Rodney
    Lesiak, Aleksandra
    Mehlis, Stephanie
    Kinoshita-Ise, Misaki
    Arenberger, Petr
    Tziotzios, Christos
    Zhang, Fan
    Law, Ernest
    Lejeune, Alexandre
    Wolk, Robert
    Woodworth, Deborah
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 125 - 126
  • [26] Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Relationship to Usage Frequency in Subjects With Epilepsy: Interim Results From a Phase 3, Open-label, Repeat Dose Study
    Miller, Ian
    Wheless, James W.
    Hogan, R. Edward
    Dlugos, Dennis
    Biton, Victor
    Cascino, Gregory D.
    Sperling, Michael R.
    Liow, Kore
    Vazquez, Blanca
    Ayala, Ricardo
    Segal, Eric B.
    Tarquinio, Daniel
    Mauney, Weldon
    Desai, Jay
    Carrazana, Enrique
    Rabinowicz, Adrian L.
    NEUROLOGY, 2020, 94 (15)
  • [27] Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma
    Duvic, Madeleine
    Horwitz, Steven M.
    Kim, Youn H.
    Zinzani, Pier Luigi
    Bhat, Gajanan
    Sharma, Pankaj
    Yancik, Sue
    BLOOD, 2015, 126 (23)
  • [28] ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study
    Piga, Antonio G.
    Perrotta, Silverio
    Melpignano, Angela
    Borgna-Pignatti, Caterina
    Voskaridou, Ersi
    Caruso, Vincenzo
    Filosa, Aldo
    Aydinok, Yesim
    Condon, Carrie
    Wilson, Dawn M.
    Laadem, Adberrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    BLOOD, 2014, 124 (21)
  • [29] Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults With Cervical Dystonia: Results From the Open-label Extension of a Phase 2 Trial
    Jankovic, Joseph
    Oh, Chad
    Liu, Yan
    Abdul-Musawir, Najeebah
    Comella, Cynthia
    TOXICON, 2024, 237 : 36 - 37
  • [30] Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with Beta-Thalassemia Major
    Yesilipek, M. Akif
    Karasu, Gulsun
    Kaya, Zuhre
    Kuskonmaz, Baris B.
    Uygun, Vedat
    Dag, Ilkiz
    Birkent, Asli
    Ertem, Mehmet
    BLOOD, 2015, 126 (23)
12345